Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITRA Trial: ALK house dust mite allergy immunotherapy tablet in house dust mite induced asthma
2010-018621-19Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- May 2010
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of house dust mite allergen extract (dermatophagoides pteronyssinus/dermatophagoides farinae) in allergic asthma and house dust mite allergy (3 arms), sponsored by ALK-Abelló. Primary endpoint: Time to first asthma exacerbation during ICS reduction. Started May 2010; status: completed.
02
Drugs
house dust mite allergen extract (dermatophagoides pteronyssinus/dermatophagoides farinae)
03
Conditions
allergic asthmahouse dust mite allergy
Beyond the preview
Go deeper on 2010-018621-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018621-19.